تحليل سهم Eli Lilly and Company (LLY) بالذكاء الاصطناعي
هل سهم LLY فرصة استثمارية جيدة؟
سهم Eli Lilly and Company (LLY) يحمل تقييم بلوتريكس للذكاء الاصطناعي 88.5/100 بتاريخ 2026/06/03، بتوصية شراء قوي. السهم ملتزم بمعايير هيئة الشريعة AAOIFI. أبرز نقاط القوة: Exceptional profitability with ROE of 101.3% and gross margins of 83.0% demonstrating superior operational efficiency and pricing power. أهم المخاوف: Elevated leverage with debt-to-equity ratio of 1.58 (24% above industry average) creating moderate financial risk.
ملخص الاستثمار
LLY represents an exceptional pharmaceutical growth story with best-in-class fundamentals that dominate this investment decision. ROE of 101.3% (vs industry ~20%) demonstrates extraordinary capital efficiency, while gross margins of 83.0% (vs industry 70%) show superior pricing power. Forward EPS growth of 22.4% next year and 26.6% over 5 years significantly outpaces industry averages of 15.2% and 8.1%. Most compelling is the PEG ratio of 0.79, indicating clear undervaluation despite PE of 39.1x. Recent news around obesity drug Foundayo's early prescription volumes (~4,000 in second week) and strategic acquisitions (Kelonia for $3.25B, Ajax for $2.3B) reinforce the growth trajectory. The analyst consensus target of $1,241.41 represents 40% upside from current $883.96.
أبرز نقاط القوة
- Exceptional profitability with ROE of 101.3% and gross margins of 83.0% demonstrating superior operational efficiency and pricing power
- Outstanding growth profile with forward EPS growth of 22.4% next year and 26.6% over 5 years, significantly above industry averages
- Attractive valuation with PEG ratio of 0.79 indicating undervaluation despite premium metrics, supported by analyst target of $1,241.41 (40% upside)
أهم المخاوف
- Elevated leverage with debt-to-equity ratio of 1.58 (24% above industry average) creating moderate financial risk
- Premium valuation metrics (PE 39.1x, P/B 31.5x) require sustained execution of growth projections to justify current levels
تقييم بلوتريكس من 10 عوامل
التحليل الأساسي
LLY exhibits exceptional financial metrics across all categories. Profitability is outstanding with ROE of 101.3% (industry ~20%), gross margin of 83.0% (vs 70% industry), operating margin of 44.9% (vs 28.2% industry), and net margin of 31.7% (vs 19.3% industry). Growth prospects are superior with forward EPS growth of 22.4% next year (vs 15.2% industry) and 26.6% over 5 years (vs 8.1% industry), supported by historical revenue growth of 42.6%. Valuation shows PEG of 0.79 indicating undervaluation despite premium PE of 39.1x. Financial health shows moderate concern with debt-to-equity of 1.58 (vs 1.27 industry) but strong cash position of $7.27 billion and free cash flow of $1.95 billion provide adequate cushion. Additional metrics: PE Ratio: 39.13
معنويات الأخبار
Eli Lilly is making bold strategic moves to cement its position as the leader in the booming obesity treatment market while expanding its oncology footprint. The pharmaceutical giant has been on an acquisition spree, announcing deals to purchase Kelonia Therapeutics for $3.25 billion and Ajax Therapeutics for up to $2.3 billion, signaling confidence in its growth strategy. The company's newly launched obesity pill Foundayo is showing promising early traction with nearly 4,000 prescriptions in just its second week, though it's facing stiff competition from Novo Nordisk's oral Wegovy in early market uptake. These developments come as Lilly continues to capitalize on the massive obesity treatment opportunity, with analysts projecting significant revenue potential from this expanding market. The acquisitions, particularly Kelonia's blood cancer therapies, demonstrate Lilly's commitment to diversifying beyond its diabetes and obesity franchise while building next-generation treatment capabilities. For investors, these moves represent Lilly's aggressive pursuit of growth opportunities in high-value therapeutic areas, though execution will be critical to justify the company's premium valuation and ambitious growth targets.
تقييم المخاطر
Primary risks include execution on obesity drug market penetration, integration of recent acquisitions, and maintaining growth rates to justify premium valuation. Debt-to-equity of 1.58 requires monitoring but strong cash flows of $1.95B provide adequate coverage. Competitive pressure in diabetes/obesity space from Novo Nordisk requires continued innovation. Mitigation through diversified pipeline, strong balance sheet, and proven execution track record.
أسهم حلال مشابهة
أسهم من نفس القطاع
الأسئلة الشائعة
هل سهم LLY حلال؟
نعم، سهم Eli Lilly and Company (LLY) حلال ومتوافق مع معايير AAOIFI وفقاً لمعايير هيئة AAOIFI للمحاسبة والمراجعة للمؤسسات المالية الإسلامية.
ما هو تقييم بلوتريكس لسهم LLY؟
يحمل سهم Eli Lilly and Company (LLY) تقييم بلوتريكس للذكاء الاصطناعي 88.5/100 بتوصية شراء قوي، بناءً على تحليل شامل من 10 عوامل يغطي الصحة المالية والنمو والتقييم والربحية والزخم الفني ومعنويات المحللين.
هل سهم LLY استثمار جيد؟
حسب التحليل الحالي لبلوتريكس، سهم LLY يحمل توصية شراء قوي بتقييم 88.5/100. للاطلاع على التحليل التفصيلي وخطة التداول، راجع الصفحة الكاملة على بلوتريكس.
كيف يمكنني الاستثمار في سهم LLY؟
يمكن للمستثمرين العرب الاستثمار في سهم LLY عبر وسطاء دوليين مثل Interactive Brokers. يوفر بلوتريكس تحليلاً شاملاً للسهم بالإضافة إلى خطط تداول ذكية تشمل نقاط الدخول ووقف الخسارة وأهداف الربح.
ما هي المخاطر الرئيسية لسهم LLY؟
يحدد الذكاء الاصطناعي في بلوتريكس المخاطر الرئيسية لسهم LLY من خلال تحليل التقييم والديون ومعنويات السوق والعوامل الكلية. للاطلاع على تقييم المخاطر الكامل، راجع قسم تقييم المخاطر في الصفحة أعلاه.